Company intelligence / Profile preview
NanoValent Pharmaceuticals, Inc.
Bozeman, Montana, United Statesnanovalent.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Lead candidate NV103 (irinotecan-anti-CD99) is approaching IND status with strong data in CD99 expressing tumor models. The platform technology has shown significant enhancement of therapeutic efficacy in preclinical studies, with NV102 increasing tumor-killing efficacy 10-12 fold in vitro compared to untargeted formulations, and NV101 showing 40-fold enhancement versus commercial Doxo-liposomes.
- Therapeutic areas
- Oncology
- Modalities
- Antibody-drug conjugates (ADC)Nanoparticle-based therapeuticsLiposomal drug delivery
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
Children's Hospital Los Angeles (CHLA)Boston University
Beyond the preview
Go deeper on NanoValent Pharmaceuticals, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NanoValent Pharmaceuticals, Inc..